Clinical Trial Update: A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC [Phase 2]

View source ↗

Summary

This is a Phase II randomized neoadjuvant trial in resectable EGFR-mutant non-small cell lung cancer comparing limertinib followed by sintilimab and chemotherap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Limertinib (Limertinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Wen-zhao ZHONG | Conditions: Resectable Non-small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING